Drug Discovery World

MAY 1, 2024

AI’s significance is also evident in the science, where immuno-oncology company Aulos Bioscience recently revealed interim results from an ongoing Phase I/II trial of an AI-designed monoclonal antibody (mAb), AU-007, in solid tumours.

FDA Approval 147

FDA Approval Therapies FDA Molecular Biology 147

LifeSciVC

AUGUST 5, 2024

The Nimbus experience to date is that this merger of scientific disciplines shows less benefit in speed and much clearer benefit in a wider range of tractable drug discovery targets and enhancement in the quality of small molecule clinical candidates developed. One final parallel to 2001.

Molecular Biology 90

Molecular Biology Production Small Molecule Drug Development 90

Drug Target Review

JUNE 19, 2024

Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy. Just like small molecules and antibodies, cell therapies are changing how we treat patients. from May 2017 until December 2022.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Discovery World

NOVEMBER 17, 2022

Lu Rahman selects some recent synthetic biology innovations and the potential they hold to benefit drug discovery. . The rapidly growing area of synthetic biology – including molecular biology, biotechnology, biophysics, and genetic engineering – is having a marked impact on the drug discovery landscape. References .

Engineering 130

Engineering Molecular Biology Synthetic Chemistry DNA 130

The Pharma Data

NOVEMBER 9, 2021

In a new study published in the journal JCI Insight, Brown University researchers describe the cellular and molecular events that explain why these groups have a higher risk of infection as well as of severe side effects and death. Elias, an immunologist and dean of medicine and biological sciences at Brown.

Small Molecule 52

Small Molecule Virus Molecular Biology Disease 52

Dark Matter Blog

JULY 16, 2021

The only subject in school that held my interest was biology. As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. I wanted to use molecular biology to create drugs. My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

Drug Discovery World

APRIL 30, 2024

It’s worth noting that the approach of small molecules interacting with mRNA biology represents a relatively new and potentially broader and more effective strategy. He has worked in life sciences and pharmaceutical B2B publishing for seven years and was previously Editor of European Pharmaceutical Manufacturer.

Therapies 130

Therapies RNA Vaccine Small Molecule 130

Drug Target Review

APRIL 19, 2024

Sibylla’s scientific founders come from very different scientific fields that do not usually speak to each other, such as theoretical physics, molecular biology and pharmaceutical chemistry. And so, I have been the managerial co-founder and CEO of Sibylla since 2017. This multidisciplinary approach is at the heart of Sibylla.

Molecular Biology 111

Molecular Biology Pharmaceuticals Small Molecule Research 111

Drug Discovery World

JULY 25, 2022

For example, we often identify endogenous ligands and natural allosteric bindings sites that can be used as putative sites for small molecules. Miguel Silva – Strategy Director at OMass Therapeutics joined OMass Therapeutics in 2020, bringing six years’ experience as a consultant within the life sciences sector.

Cell Based Assays 130

Cell Based Assays Drugs Pharmaceutical Companies Molecular Biology 130

Elrig

APRIL 29, 2024

My role involved generating and characterizing complex proteins critical for biological assay development, hit discovery, and structural biology. During this time, I had the opportunity to step in as an interim Discovery Sciences project lead, sparking my interest in project leadership.

Bioinformatics 59

Bioinformatics Molecular Biology Drugs Cell Based Assays 59

Drug Discovery World

NOVEMBER 15, 2022

Anita Ramanathan outlines four synthetic biology approaches that are improving and accelerating drug discovery. . As such, the synthesis of DNA oligonucleotides for routine molecular biology applications is often outsourced to service provider companies that operate DNA synthesisers to meet these demands. .

DNA 246

DNA Engineering Drugs Vaccine 246

The Pharma Data

SEPTEMBER 15, 2020

The companies will receive priority admission or renewal for one year of lab bench space with access to core facilities at the MBC BioLabs life sciences incubator, including access to Amgen ‘s scientific experts and business leaders to help advance their scientific programs.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Small Molecule Science 52

Drug Target Review

FEBRUARY 15, 2024

Advances in molecular biology have led to highly safe, efficient, and effective platforms, such as mRNA, that can be rapidly re-purposed for different pathogens, multiple pathogens, or new strains of evolving pathogens. 2023 May 12; Available from: [link] National Academies of Sciences, Engineering, and Medicine.

Drug Development 122

Drug Development Virus Vaccine Government 122